Contineum Therapeutics (NASDAQ:CTNM) Stock Price Up 2.2% - Here's What Happened

Key Points

• Shares rose 2.2% to $13.25 (intraday high $13.46) on heavy volume of 1,154,066 shares, a 294% increase versus average trading volume.
• Analyst sentiment is mixed but tilted positive: Robert W. Baird raised its target to $20 with an "outperform" rating, and the consensus from analysts is a "Moderate Buy" with an average target around $19.50.
• Contineum is a clinical-stage biopharma (market cap ≈ $495M) with negative earnings (P/E -6.08); it slightly beat quarterly EPS estimates and its lead asset is PIPE-791, targeting idiopathic pulmonary fibrosis and progressive MS.

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report)'s stock price shot up 2.2% on Wednesday . The stock traded as high as $13.46 and last traded at $13.25. 1,154,066 shares traded hands during trading, an increase of 294% from the average session volume of 293,095 shares. The stock had previously closed at $12.97.

Analysts Set New Price Targets

A number of research analysts have commented on CTNM shares. Robert W. Baird upped their price objective on Contineum Therapeutics from $14.00 to $20.00 and gave the company an "outperform" rating in a report on Friday, March 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen cut Contineum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $14.00 price objective (down from $23.00) on shares of Contineum Therapeutics in a research report on Thursday, January 8th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $19.50.

Contineum Therapeutics Stock Up 2.2%

The company's fifty day moving average price is $13.96 and its 200 day moving average price is $12.43. The company has a market capitalization of $494.76 million, a P/E ratio of -6.08 and a beta of 1.38.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last announced its earnings results on Thursday, March 5th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.01. Research analysts predict that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CTNM. Strs Ohio bought a new position in Contineum Therapeutics in the first quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. bought a new position in Contineum Therapeutics in the fourth quarter valued at approximately $43,000. Qube Research & Technologies Ltd bought a new position in Contineum Therapeutics in the second quarter valued at approximately $43,000. Marex Group plc bought a new position in Contineum Therapeutics in the second quarter valued at approximately $45,000. Finally, Bridgeway Capital Management LLC bought a new position in Contineum Therapeutics in the second quarter valued at approximately $76,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.